Linked Data API

Show Search Form

Search Results

753310
star this property registered interest false more like this
star this property date less than 2017-07-18more like thismore than 2017-07-18
star this property answering body
Department for Business, Energy and Industrial Strategy more like this
star this property answering dept id 201 more like this
unstar this property answering dept short name Business, Energy and Industrial Strategy more like this
star this property answering dept sort name Business, Energy and Industrial Strategy more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what action they are taking to increase the use of rooftop solar power. more like this
star this property tabling member printed
Lord Kennedy of Southwark more like this
star this property uin HL998 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-07-27more like thismore than 2017-07-27
star this property answer text <p>Solar PV is a UK success story. In 2013 we estimated that solar capacity would reach 10-12GW by 2020. We now expect Government support to bring forward around 13 GW by 2020. The Feed-in Tariff remains open to solar PV which provides an incentive for businesses to invest in rooftop solar.</p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2017-07-27T13:33:03.163Zmore like thismore than 2017-07-27T13:33:03.163Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4153
unstar this property label Biography information for Lord Kennedy of Southwark more like this
386888
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton remove filter
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton remove filter
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386886
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton remove filter
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386885
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Myeloma more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government when they expect the National Institute of Health Research Technology Assessment programme to publish initial findings from its assessment of the benefits of antibiotic prophylaxis and its effect on healthcare associated infections in myeloma patients. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL994 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>This trial is led by the University of Birmingham. The project is recruiting ahead of schedule and expects to reach its target of 800 in the near future. The target was to do so by the end of November 2015. Publication of initial findings is expected in 2017.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2015-07-09T13:00:57.7Zmore like thismore than 2015-07-09T13:00:57.7Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386884
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL993 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2015-07-14T15:36:20.96Zmore like thismore than 2015-07-14T15:36:20.96Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
753296
star this property registered interest false more like this
star this property date less than 2017-07-18more like thismore than 2017-07-18
star this property answering body
Department for Business, Energy and Industrial Strategy more like this
star this property answering dept id 201 more like this
unstar this property answering dept short name Business, Energy and Industrial Strategy more like this
star this property answering dept sort name Business, Energy and Industrial Strategy more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text Her Majesty's Government what is the budget of the Employment Agency Standards Inspectorate for 2017–18; how many staff it expects to employ in 2017–18; and how many staff it employed in each of the last five years. more like this
star this property tabling member printed
Baroness Jolly more like this
star this property uin HL984 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2017-07-27more like thismore than 2017-07-27
star this property answer text <p>The Employment Agency Standards (EAS) Inspectorate currently employs thirteen members of staff and has a budget of £750,000 for the financial year 2017/18.</p><p> </p><p>The table below details the number of staff employed by EAS in the last five years:</p><p> </p><table><tbody><tr><td><p><strong>Year</strong></p></td><td><p><strong>Number of Full Time Equivalent Staff as of the 1st April for each year</strong></p></td></tr><tr><td><p>2012/13</p></td><td><p>16</p></td></tr><tr><td><p>2013/14</p></td><td><p>12</p></td></tr><tr><td><p>2014/15</p></td><td><p>2 (supported by an Administrative Officer)</p></td></tr><tr><td><p>2015/16</p></td><td><p>11</p></td></tr><tr><td><p>2016/17</p></td><td><p>11</p></td></tr><tr><td><p>2017/18</p></td><td><p>13</p></td></tr></tbody></table><p> </p><p> </p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2017-07-27T13:32:45.117Zmore like thismore than 2017-07-27T13:32:45.117Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4203
unstar this property label Biography information for Baroness Jolly more like this
386488
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Innovative Medicines and Medical Technology Review more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what opportunities will be available to participate in the Accelerated Access Review announced in November 2014 as "The Innovative Medicines and Medical Technology Review" for (1) the public and patient groups, (2) medical charities, (3) academics, (4) researchers, and (5) other interested parties; and when they expect it to report. more like this
star this property tabling member printed
Baroness Gardner of Parkes more like this
star this property uin HL983 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>In order to inform his recommendations, the independent chair of the Accelerated Access Review, Sir Hugh Taylor, will be seeking views from a variety of stakeholder groups, including patients and their carers, medical charities, academics and researchers, as well as industry, the National Health Service and key arm’s length bodies such as the National Institute for Health and Care Excellence and NHS England. We have agreed a systematic engagement approach for these groups to ensure they all have the opportunity to input. A workshop involving representation from all these stakeholder groups was held on 2 July, and the review team is asking umbrella organisations and trade bodies to support it in continuing to reach a wide audience by holding a series of engagement events throughout the summer; these events are currently being planned. The review’s website is also being developed to include a crowdsourcing platform to allow these groups, and the wider public, to participate.</p><p> </p><p> </p><p> </p><p>We expect the report of the Accelerated Access review to be submitted by the end of the year.</p><p> </p>
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2015-07-09T13:00:31.627Zmore like thismore than 2015-07-09T13:00:31.627Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
3596
unstar this property label Biography information for Baroness Gardner of Parkes more like this
518804
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Funeral Payments more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the impact of Health Education England’s demand-led approach to the assessment of the number of consultant posts needed in highly specialist fields such as clinical pharmacology. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL98 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-25more like thismore than 2016-05-25
star this property answer text <p>It is Health Education England’s responsibility to ensure that there is sufficient future supply of staff, including those needed in specialist fields, to meet the workforce requirements of the English health system.</p><p> </p><p>The Workforce Plan is built upon the needs of local employers, providers, commissioners and other stakeholders who, as members of its Local Education Training Boards (LETBs), shape the thirteen local plans.</p><p> </p><p>The Workforce Plan is predominately an aggregate of the local LETB plans, but the final national plan is only agreed with the advice and input of its clinical advisory groups and Patients’ Advisory Forum, as well as the Royal Colleges and other stakeholders.</p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2016-05-25T13:52:12Zmore like thismore than 2016-05-25T13:52:12Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
386477
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hepatitis: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what steps they are taking to ensure that NHS England provides patients with hepatitis C access to new drugs approved by the National Institute for Health and Care Excellence without delay, and to ensure that NHS England continues to assess new technologies based on cost-effectiveness rather than affordability. more like this
star this property tabling member printed
Baroness Randerson more like this
star this property uin HL972 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>Commissioners are legally required to fund drugs and treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance.</p><p> </p><p> </p><p> </p><p>In the absence of guidance from NICE, it is for commissioners, including NHS England, to make funding decisions based on the available evidence.</p><p> </p><p> </p><p> </p><p>Commissioners are required to have in place clear and transparent arrangements for local decision making and for considering individual funding requests taking into account patients’ clinical circumstances.</p><p> </p> more like this
star this property answering member printed Lord Prior of Brampton remove filter
star this property question first answered
less than 2015-07-09T12:59:51.583Zmore like thismore than 2015-07-09T12:59:51.583Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton more like this
star this property tabling member
4230
unstar this property label Biography information for Baroness Randerson more like this